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Abstract: Cholangiocarcinoma (CCA) is a highly aggressive malignancy that emerges from the
biliary tree. There are three major classes of CCA—intrahepatic, hilar (perihilar), or distal
(extrahepatic)—according to the location of tumor development. Although CCA tumors are mainly
derived from biliary epithelia (i.e., cholangiocytes), CCA can be originated from other cells, such as
hepatic progenitor cells and hepatocytes. This heterogeneity of CCA may be responsible for poor
survival rates of patients, limited effects of chemotherapy and radiotherapy, and the lack of treatment
options and novel therapies. Previous studies have identified a number of neuroendocrine mediators,
such as hormones, neuropeptides, and neurotransmitters, as well as corresponding receptors. The
mediator/receptor signaling pathways play a vital role in cholangiocyte proliferation, as well as
CCA progression and metastases. Agonists or antagonists for candidate pathways may lead to
the development of novel therapies for CCA patients. However, effects of mediators may differ
between healthy or cancerous cholangiocytes, or between different subtypes of receptors. This review
summarizes current understandings of neuroendocrine mediators and their functional roles in CCA.
Keywords: cholangiocarcinoma; cholangiocytes; ductular reaction; liver fibrosis; neurotransmitters;
neuropeptides; hormones
1. Introduction
Cholangiocarcinoma (CCA) is a biliary tract cancer with multiple liver cell involvement, which
is highly malignant [1]. CCA is one of the most fatal cancers because early diagnosis is challenging,
and treatment options are scarce [1]. Treatments for CCA include chemotherapy and radiotherapy,
liver transplantation, or surgical resection [1,2]. However, patients with curative surgeries often
have recurrence and distant malignancies, and chemotherapy has only limited effects due to genetic
mutations or aberrations resulting in chemoresistance [2]. As a result, the five year survival rate is less
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than 30% [3,4]. CCA is the second most common primary hepatic malignancy after hepatocellular
carcinoma (HCC) and accounts for approximately 20% of deaths from hepatobiliary cancers [3].
In addition, the incidence of CCA has been increasing in recent years probably due to the increased
incidence of metabolic syndromes and obesity, which are risk factors for CCA development [5].
CCA is heterogeneous and can be classified depending on the location where the tumor emerges:
intrahepatic, hilar or perihilar, or distal or extrahepatic CCA [6]. The origins of CCA tumors can also be
heterogeneous. The majority of CCA tumors, especially for hilar and distal CCA, are derived from the
bile duct epithelia (i.e., cholangiocytes). In rare cases of intrahepatic CCA, liver stem cells or hepatic
progenitor cells behave as cancer stem cells and develop as CCA tumors [7,8] In addition, hepatocytes
can transdifferentiate into cancerous biliary phenotypes in rodents, indicating that intrahepatic CCA
tumors can be derived from hepatocytes [9,10]. These heterogeneous characteristics may be responsible
for poor survival rates of patients and limited effects of current therapies such as chemotherapy.
Primary sclerosing cholangitis (PSC) is a type of cholangiopathy, which is characterized by
cholestasis, biliary inflammation, ductular reaction, and liver fibrosis [11]. It is known that PSC patients
have high risks of CCA development, and a previous study using 211 PSC patients reported that
the risk of CCA after 10 or 20 years was both 9%, indicating the strong association between PSC and
CCA [12]. Although detailed mechanisms of the development of CCA tumors are undefined, previous
studies have identified a number of neurotransmitters, hormones, and peptides that are associated
with cholangiocyte functions in PSC as well as CCA development. These associated mediators and
their receptors may have the potential as novel therapeutic targets to inhibit CCA development or
progression. This review summarizes current understandings of neuroendocrine changes in the liver
associated with CCA.
2. Functional Roles of Neuroendocrine Mediators in Cholangiocarcinoma
2.1. Hormones
2.1.1. Secretin
Secretin (Sct) is a hormone produced predominantly by S cells of the duodenum [13].
Cholangiocytes also secrete Sct and express its receptor (secretin receptor, SR), which is upregulated
when cells are activated [14]. Sct induces cholangiocyte proliferation via elevated cAMP levels leading
to ductular reaction in healthy rats in vivo [15]. Cholangiocyte activation and proliferation is mediated
by decreased levels of microRNA (miRNA) let-7a and miR-125b as well as elevated levels of their
targets, nerve growth factor (NGF) and vascular endothelial growth factor (VEGF), and the Sct/SR
axis is essential in this process [16]. Bile duct ligation (BDL), which is a surgical procedure to mimic
cholestasis in rodents, causes ductular reaction, liver inflammation, and fibrosis [17]. Knocking out of
Sct or SR improved liver conditions of BDL mice by inhibiting activation and fibrogenesis in hepatic
stellate cells (HSCs) [18]. Transgenic mice with knockout of multidrug resistance protein 2 (Mdr2-/-
mice) are the most common transgenic animal model of human PSC [17]. Depletion of SR in Mdr2-/-
mice attenuated ductular reaction and liver fibrosis by decreasing cellular senescence in cholangiocytes
in vivo [19]. The Sct/SR axis is a promising therapeutic target to regulate cholangiocyte functions
followed by liver fibrosis [18,20]. SR is expressed only in cholangiocytes in the liver [21,22]. CCA
tumors have biliary phenotypes and are positive for biliary markers such as cytokeratin-7 (CK-7) and
CK-19 in immunohistochemistry [23]. If the origin of CCA tumors is cholangiocytes, these tumors
are also positive for SR. A previous study analyzed 10 cirrhotic liver tissues, 35 CCA tumors, and
45 HCC tumors and found that SR was upregulated with ductular reaction in cirrhotic livers [24].
Sixty-three percent of CCA tumors were positive to SR, but no HCC tumors expressed SR [24]. These
studies support that HCC tumors do not express SR and suggest that the majority of CCA tumors are
cholangiocyte-derived (63% in this study), but there are other phenotypes that are derived from different
hepatic cells and do not express SR. Although Sct induces cell proliferation in normal cholangiocytes,
it has opposite effects on CCA. Sct treatment decreased cell proliferation in human CCA cell lines,
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Mz-ChA-1, SG231, HuH-28, CCLP, HuCCT1, and TFK-1 cells, but increased proliferation of normal
human cholangiocytes in vitro [25]. Sct elevated cAMP levels in normal cholangiocytes but not in
Mz-ChA-1 cells, and Sct administration decreased tumor size in Mz-ChA-1 xenograft mice in vivo [25].
Although the Sct/SR axis may be useful as a therapeutic target for CCA using Sct administration or
SR agonists, Sct production is upregulated in PSC cholangiocytes and it is unclear how CCA tumors
emerge in this condition. In addition, since the limited percentages of CCA tumors are positive for SR,
the efficacy of Sct treatment will also be limited only to SR-positive CCA patients.
2.1.2. Somatostatin
Somatostatin is a hormone secreted from various organs including the brain, the pancreas, and the
gut [26]. Somatostatin functions as an inhibitory hormone which regulates cell proliferation and
secretion of hormones in various types of cells [26]. Cholangiocytes express receptors of somatostatin
and can be regulated especially via somatostatin receptor subtype 2 (SSTR2) [27]. Sct induces elevation
of cAMP levels and cell proliferation in cholangiocytes as mentioned, and somatostatin abolishes these
effects and inhibits cholangiocyte proliferation [28]. A previous study using seven CCA tumor tissues
found that all CCA tumors expressed mRNA of SSTR2 [29]. A somatostatin analogue, octreotide,
inhibited cell proliferation of human CCA line SK-ChA-1 cells, and another analogue, lanreotide,
decreased tumor weights in SK-ChA-1 xenograft mice, indicating the potentials of somatostatin or its
analogues as therapeutic drugs for CCA [29]. Analysis of mRNA expression for SSTR isoforms (subtype
1 to 5) in CCA cell lines, QBC939, RBE, NEC, and SSP25, detected only SSTR2 in these cell lines [30].
Octreotide administration into QBC939 xenograft mice decreased the tumor size [30]. However, a study
using 20 patients with CCA or gallbladder adenocarcinoma found that administration of lanreotide
had minimal therapeutic effects with no significant improvement of tumor conditions, regardless of
the detection of SSTR in patients by radiolabeled somatostatin analogues [31]. In addition, histological
analysis using 27 CCA tumor tissues detected SSTR2 from only 30% of CCA tumors [32]. This study
identified other SSTR isoforms from CCA tissues; SSTR1 was detected from 67% of CCA tumors,
SSTR5 was from 11%, and SSTR3 and SSTR4 were not detected [32]. Although administration of
somatostatin or its analogues may be therapeutic to inhibit CCA progression, further studies are
required to evaluate their effects in human patients, and responses against somatostatin treatments
may differ depending on CCA phenotypes with different expression levels of SSTR and its subtypes in
the tumor.
2.1.3. Melatonin
Melatonin is a hormone secreted predominantly in the pineal gland from serotonin. Serotonin
is converted to melatonin by aralkylamine N-acetyltransferase (AANAT) and acetyl serotonin
O-methyltransferase (ASMT) [33]. Cholangiocytes express AANAT and ASMT as well as melatonin
receptors MT1 and MT2, indicating the local melatonin production and signaling in the liver [34].
Melatonin has inhibitory effects on cholangiocytes, and melatonin administration or overexpression of
AANAT decreased cAMP levels and VEGF expression in cholangiocytes, leading to decreased ductular
reaction in BDL rats in vivo [35–37]. Melatonin administration also decreased ductular reaction and
liver fibrosis in Mdr2-/- mice by inhibiting cholangiocyte proliferation and HSC fibrogenesis, suggesting
that melatonin can be utilized as a therapeutic drug for PSC [38]. A previous study has demonstrated
that expression levels of AANAT and ASMT are downregulated in human CCA line Mz-ChA-1
cells compared to human normal cholangiocyte line H69 cells, and melatonin treatments inhibited
Mz-ChA-1 cell proliferation and decreased tumor size in xenograft mice by inducing apoptosis in CCA
cells, supporting the melatonin-mediated autocrine regulation of cholangiocytes or CCA cells [39].
Another study also demonstrated the inhibitory effects of melatonin on CCA cell proliferation using
KKU-M055 and KKU-M214 cells [40]. Infection with liver flukes, such as Opisthorchis viverrini and
Clonorchis sinensis, is a common risk factor for CCA development in Asia [4]. Liver fluke infestation
was utilized with the combination of carcinogen administration, N-nitrosodimethylamine, to induce
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CCA tumors in hamsters [41]. In this model, melatonin administration decreased CCA tumor size
and improved survival rates of affected hamsters by inhibiting apoptosis and restoring functions of
mitochondria [41]. CCA tumors are often accompanied by dense stromal tissues including immune
cells. Melatonin administration decreased the population of CD4+, IL-17+, and FOXP3+ cells in the
liver, which probably leads to the inhibition of CCA tumor growth in this hamster model [42]. These
studies suggest the promising therapeutic effects of melatonin against CCA; however, it is undefined
whether melatonin can be effective on all CCA phenotypes since CCA tumors may have different
expression levels of melatonin receptors, and responses against melatonin may differ depending on
CCA tumors with different origins.
2.1.4. Estrogen
Estrogen is a primary female sex hormone produced mainly in ovaries and binds to two types of
estrogen receptors, ER-α and ER-β [43]. Cholangiocytes express both ER-α and ER-β, but at normal
conditions, expression levels of these receptors are barely detectable [44,45]. Interestingly, expression
levels of both ER-α and ER-β are upregulated at diseased conditions including PSC and alcoholic
cirrhosis [44]. BDL elevated ER-α and ER-β expression in cholangiocytes in vivo, and treatment with
17β-estradiol, a type of estrogen, induced cell proliferation of primary cholangiocytes isolated from
normal rats [45]. CCA tumors had high levels of ER-α and ER-β detected by immunohistochemistry,
indicating the regulations of cholangiocytes and CCA cells by estrogen [44]. A previous study has
demonstrated that 17β-estradiol induces cell proliferation and decreases apoptosis in human CCA
line HuH-28 cells [46]. Another study found that CCA tumors expressed high levels of VEGF-A
and VEGF-C, and 17β-estradiol elevated expression levels of these VEGFs and their receptors in
HuH-28 cells leading to increased cell proliferation [47]. Glyphosate, which is a common herbicide
used worldwide, has been reported to activate ER-α leading to elevated cell proliferation under
unknown mechanisms [48]. Stimulation of HuCCT1 cells, which express both ER-α and ER-β, with
17β-estradiol or glyphosate at the same concentrations increased cell proliferation by activating the
ERK1/2 pathway [49]. Administration of 17β-estradiol induced cell proliferation in human CCA line
KKU-213 and KKU-139 cells and increased tumor weights in xenograft mice with either of these
CCA cells [50]. In fact, administration of an estrogen receptor modulator, tamoxifen, abolished these
proliferative effects of estrogen [50]. Therefore, these studies suggest that estrogens and activation of
their receptors induce CCA tumor growth.
Since estrogens are female hormones, these results raise a question whether females are more
susceptible to CCA than males. A statistical analysis has shown that the incidence of intrahepatic
CCA in the US is increasing in both males and females, and males have higher incidence than
females [51]. Another study analyzed CCA mortality in the US and found that females had lower
mortality rates compared to males, indicating that higher estrogen levels in women do not increase
the susceptibility of CCA formation or progression [52]. Functions of estrogen receptors may differ
between ER-α and ER-β. Thioacetamide (TAA) is a carcinogen which induces liver fibrosis, cirrhosis,
and CCA [53,54]. Administration of KB9520, a selective ER-β agonist, decreased cell proliferation
and increased apoptosis in HuH-28 cells in vitro [55]. KB9520 also inhibited CCA tumor formation
as well as tumor growth after tumor formation in TAA-induced CCA rat models [55]. Genistein is
another ER-β agonist, and treatments with genistein inhibited cell proliferation of human intrahepatic
CCA lines (HuCCT1 and RMCCA-1) by decreasing activation of AKT and ERK1/2 signaling pathways,
indicating that activation of ER-α or ER-β results in different effects in CCA cells [56]. In addition,
CCA may change estrogen production and secretion regardless of gender. A previous study analyzed
serum samples from 54 male CCA patients and 68 male healthy individuals and found that CCA
patients had significantly higher serum estrogen levels than control subjects, and these high levels of
estrogen were correlated with poor survival rates [57]. Aromatase (CYP19A1) is a key enzyme for the
production of estrogens. A study using CCA tumor tissues from 51 males and 23 females found that
CCA tumors had elevated expression of aromatase, and high aromatase expression was correlated
Cells 2020, 9, 436 5 of 17
with poor survival rates in males but not in females [58]. CCA line KKU-100 and KKU-213 cells also
express elevated levels of aromatase compared to normal cholangiocytes, and inhibition of aromatase
expression by siRNAs decreased cell proliferation and migration in KKU-213 cells [58]. Although
the inhibition of estrogen production especially in males may be a promising therapeutic approach,
further studies are required to elucidate detailed mechanisms and functional roles of local estrogen
production in the liver and activation of signaling pathways via ER-α or ER-β receptors.
2.1.5. Insulin-Like Growth Factor
Insulin-like growth factor (IGF) is a hormone which has high similarity to insulin and may
be associated with cancer development [59]. There are two types of IGF, IGF-1 and IGF-2,
and corresponding receptors, IGF-1R and IGF-2R. RT-PCR detected expression of both IGF-1R
and IGF-2R in human CCA lines including HuH-28 and TFK-1 cells [60]. Immunohistochemistry
detected elevated expression levels of IGF-1 and IGF-1R in CCA tumors compared to normal liver
tissues [46]. IGF-1 treatments induced cell proliferation of HuH-28 cells by elevated activation of
AKT and ERK1/2 signaling pathways [46]. CCA cells often express elevated levels of epidermal
growth factor receptor (EGFR). IGF-1, EGF, and estradiol induce cancer cell adhesion via IGF1R and
activation of ERK1/2 [61]. Tyrosine kinase inhibitors, such as erlotinib, inhibit EGFR activation and
have anti-cancer effects, although CCA tumors often have resistance to EGFR inhibitors [62]. Vaquero
et al. generated erlotinib-resistant CCA cells by escalating exposure to erlotinib from 1 to 20 µM and
found that resistant CCA lines, including Mz-ChA-1, HuCCT1, and SK-ChA-1 cells, expressed higher
levels of IGF-2 and IGF-1R as well as insulin receptor (IR) [63]. IR/IGF-1R inhibitor, linsitinib, decreased
tumor volumes in xenograft mice with erlotinib-resistant CCA tumors [63]. A study analyzing serum
and bile samples of 29 patients with extrahepatic CCA, 19 patients with pancreatic cancer, and 25
patients with benign biliary abnormalities found that CCA patients have significantly elevated levels
of IGF-1 in bile compared to other patient groups but not in serum [64]. Another study using samples
from 62 patients with biliary obstructions, such as PSC or chronic pancreatitis, and 47 patients with
malignant biliary obstructions including CCA and head of pancreas tumor demonstrated that patients
with malignant obstructions had increased levels of IGF-1 and VEGF in bile but not in serum [65].
Malignancies in the bile ducts are strongly associated with IGF in bile, and inhibition of IGF signaling
may be a promising target to develop novel therapies for CCA.
2.1.6. Gastrin
Gastrin is a gastrointestinal hormone that regulates gastric acid secretion [66]. Gastrin binds
to the cholecystokinin B receptor (CCK-BR), and cholangiocytes express this receptor indicating
the regulation of cholangiocyte functions by gastrin [67]. Sct induces secretion and proliferation of
cholangiocytes by elevating cAMP levels, and gastrin abolishes these effects [67]. Administration of
gastrin inhibited ductular reaction and cholangiocyte proliferation by decreasing cAMP levels in BDL
rats in vivo, suggesting its inhibitory effects on cholangiocytes [68]. Histological analysis using 10 CCA
tumor tissues identified elevated expression levels of CCK-BR and gastrin precursors in CCA tumors,
indicating local gastrin production and signaling activation in CCA tumors [69]. CCA lines, Mz-ChA-1,
HuH-28, and TFK-1 cells, expressed CCK-BR, and gastrin treatments decreased cell proliferation in
CCA cells by inducing apoptosis via elevated inositol 1,4,5-triphosphate (IP3) secretion and protein
kinase C alpha (PKC-α) expression [70]. Although these studies suggest the anti-cancer effects of
gastrin against CCA, previous studies are limited, and detailed mechanisms are undefined.
2.2. Neuropeptides
2.2.1. Nerve Growth Factor
NGF is a neuropeptide associated with cell growth and plays an important role with VEGF
in cholangiocyte proliferation as mentioned [16]. During BDL, NGF expression is upregulated in
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cholangiocytes, leading to elevated ductular reaction and biliary inflammation in rodents [71,72].
CCA tumors express elevated levels of VEGF [47]. Immunohistochemistry for 28 hilar CCA tumor
tissues identified elevated NGF-β expression in 57.1% of CCA cases, and robust NGF-β expression
was positively correlated with elevated VEGF-C expression, indicating the association of NGF-β with
CCA proliferation [73]. Another study has demonstrated that NGF-β is overexpressed in human CCA
line QBC939 cells, and induces tumor growth in xenograft mice models [74]. NGF has two receptors,
low affinity p75 neurotrophin receptor (p75NTR) and high affinity tropomyosin receptor kinase A
(TrkA) [75]. A study using 83 intrahepatic CCA samples has demonstrated that NGF and TrkA are
upregulated in CCA tumors, and high levels of NGF and TrkA expression are associated with poor
survival rates of patients [76]. NGF-β treatments induced cell proliferation and invasion of human
intrahepatic CCA line RBE cells [76]. However, immunohistochemistry for 112 extrahepatic CCA
samples demonstrated that 55% of patients had high NGF expression and 45% of patients had low
expression, and there was no significant association between NGF expression levels and survival
rates [77]. In addition, previous studies showing the association between NGF and CCA have been
reported form Asian countries, and a study analyzing 93 CCA tumor tissues from Caucasian patients
has reported that NGF-β and all Trk isoforms (A, B, and C) could not be detected from these Caucasian
samples, regardless of the location of CCA (intrahepatic, hilar, or distal) [78]. NGF-Trk signaling could
be a therapeutic target for the novel CCA therapy, the efficacy may differ between races, and genetic
traits may be involved in NGF-mediated CCA growth.
2.2.2. Substance P
Substance P (SP) is a neuropeptide which binds to neurokinin 1 receptor (NK-1R) with high
affinity [79]. BDL elevates serum levels of SP in rats [80], and mRNA expression levels of NK-1R and
tachykinin precursor 1 (TAC1), which encodes the precursor of SP, are upregulated in liver samples
of BDL mice, Mdr2-/- mice, and late stage PSC patients [81]. Administration of SP caused elevated
ductular reaction and liver fibrosis in C57BL/6 wild-type mice, and NK-1R-/- mice had improved liver
conditions after BDL compared to wild-type mice with decreased HSC activation and fibrogenesis,
indicating the association between the SP/NK-1R axis and cholestatic liver injury [81]. Human CCA
lines, Mz-ChA-1, SG231, HuH-28, CCLP, and HuCCT1 cells, express higher levels of TAC1 and NK-1R
compared to human normal cholangiocytes [82]. SP increased cell proliferation of these CCA cell lines,
and administration of NK-1R antagonist, L-733,060, decreased Mz-ChA-1 cell proliferation in vitro as
well as tumor size in Mz-ChA-1 xenograft nude mice in vivo [82]. Although NK-1R antagonists may
be therapeutic in inhibiting CCA tumor growth, current studies are limited and expression levels of
TAC1 and NK-1R in human CCA tumor tissues and correlation with metastases or survival rates are
still undefined.
2.2.3. Neuropeptide Y
Neuropeptide Y (NPY) regulates various biological actions in the gastrointestinal tract via NPY
receptors, and five subtypes of NPY receptors have been identified in mammals [83,84]. NPY is
a physiological substrate of fibroblast activation protein, which is strongly associated with liver
fibrosis via HSC activation [85]. A previous study has demonstrated that BDL elevated expression of
NPY in the rat bile ducts [86]. Administration of NPY or anti-NPY antibody decreased or increased
ductular reaction in BDL rats, respectively, indicating the inhibitory effects of NPY on cholangiocyte
proliferation [86]. Immunohistochemistry identified elevated NPY levels in CCA tumor samples
from 48 patients [87]. NPY treatments inhibited cell proliferation of CCA lines, Mz-ChA-1, SG231,
HuH-28, CCLP, HuCCT1, and TFK-1 cells, via elevation of IP3 secretion and PKC-α activation [87].
Administration of NPY decreased tumor volume in Mz-ChA-1 xenograft mice, indicating promising
anti-cancer effects against CCA, although current studies are limited and further experimental evidence
is required [87].
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2.3. Neurotransmitters
2.3.1. Dopamine
Dopamine is a neurotransmitter, which plays an important role in the brain. Parkinson’s disease
is a common neurological disorder in the elderly characterized by degeneration of dopaminergic
neurons. Dopaminergic denervation is associated with liver malfunctions, indicating the regulations
of liver functions by dopamine [88]. There are five subtypes of dopamine receptors identified to date,
and BDL elevates expression levels of D2 dopamine receptor in rat cholangiocytes [89]. Treatments
with an agonist for D2 and D3 receptor, quinelorane, inhibited upregulation of cAMP levels and
PKA activity induced by Sct in cholangiocytes [89]. Since elevated cAMP and PKA activity induces
proliferation and secretion of cholangiocytes [90], this study suggests that dopamine has the inhibitory
effects on cholangiocyte proliferation and functions. Dopamine is converted from tyrosine by enzymes
tyrosine hydroxylase (TH) and dopa decarboxylase (DDC), and a previous study found that CCA
tumors had higher expression levels of TH and DDC compared to normal liver tissues detected by
immunohistochemistry using 48 CCA tumor tissues [91]. Human CCA lines, Mz-ChA-1, SG231, CCLP,
and HuCCT1 cells, had significantly higher levels of dopamine secretion as well as TH and DDC
expression compared to normal cholangiocytes [91]. Dopamine treatments induced CCA cell line
proliferation, and administration of a specific DDC inhibitor, L-(-)-α-methyldopa, decreased tumor
volumes in Mz-ChA-1 xenograft mice in vivo [91]. Although inhibition of local dopamine production
in CCA tumors could be a therapeutic approach, current studies are limited, and further studies are
needed to evaluate the efficacy of TH or DDC inhibitors as drugs for CCA.
2.3.2. Serotonin
Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter associated with sleeping, mood and
depression, eating and digestion, and cancer development [92]. Serotonin is synthesized from
tryptophan by tryptophan hydroxylase (TPH), and degraded by monoamine oxidase (MAO) [93].
TPH1-/- mice had higher liver damage and necrosis after BDL compared to wild-type mice via elevated
bile salt secretion, indicating the inhibitory effects of serotonin on cholangiocyte proliferation and
secretion [94]. There are seven families of serotonin receptors with a number of subtypes, which have
different functions and characteristics [93]. Cholangiocytes express serotonin receptors 5-HT1A and
5-HT1B during BDL, and administration of serotonin receptor agonists (8-OH-DPAT for 5-HT1A and
anpirtoline for 5-HT1B) decreased BDL-induced ductular reaction and cholangiocyte proliferation
by inhibiting elevation of cAMP and PKA activity [95]. However, a recent study has demonstrated
that cholangiocytes express other receptor subtypes, 5-HT2A, 5-HT2B, and 5-HT2C, and agonists for
these receptors exacerbated ductular reaction and liver fibrosis in BDL rats [96]. Antagonists of
these receptors attenuated BDL-induced liver damage in vivo, indicating that activation of serotonin
receptors affects liver conditions differently depending on the receptor [96]. Immunohistochemistry
for 48 samples from CCA patients identified elevated expression levels of TPH1 and decreased levels
of MAO-A in CCA tumors [97]. CCA patients had higher serotonin levels in bile compared to control
individuals, and human CCA cell lines, Mz-ChA-1, SG231, HuH-28, CCLP, HuCCT1, and TFK-1 cells,
also secrete higher levels of serotonin compared to normal cholangiocyte H69 cells [97]. Serotonin
treatments induced cell proliferation in CCA cell lines in vitro, and administration of a specific TPH1
inhibitor, p-chlorophenylalanine, decreased tumor volume in Mz-ChA-1 xenograft mice in vivo [97].
A previous study analyzed intra-platelet serotonin levels in 96 patients with liver cancers, including
colorectal cancer liver metastasis, HCC, and CCA, and found that high serotonin levels were associated
with increased incidence of postoperative disease recurrence, indicating the promotion of cancer
growth by serotonin [98]. Another study using 43 intrahepatic CCA and 84 hilar CCA tumor tissues
found that expression levels of MAO-A were significantly downregulated in CCA tumors compared
to 45 benign tissues [99]. No or low MAO-A expression was correlated with poor survival rates of
CCA patients [99]. Overexpression of MAO-A in Mz-ChA-1 cells decreased cell proliferation as well as
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tumor volumes in xenograft mice [99]. Although inhibition of TPH1 to decrease serotonin production
or expression of MAO-A to promote serotonin degradation may be a promising therapeutic approach
for CCA, functional roles of serotonin receptors may differ depending on the subtype, and further
studies are required to elucidate the detailed mechanisms.
2.3.3. Histamine
Histamine is a mediator, which is predominantly secreted from mast cells and associated
with allergic and inflammatory responses via interaction with four subtypes of histamine receptors
(H1-H4) [100]. Previous studies have demonstrated that serum histamine levels are upregulated in
BDL rats or Mdr2-/- mice, and administration of cromolyn sodium, which stabilizes mast cells and
inhibits histamine secretion, attenuates ductular reaction and liver fibrosis in those animals, indicating
that histamine promotes cholangiocyte proliferation [101,102]. Histamine is converted from histidine
by histidine decarboxylase (HDC) and degraded by MAO-B, and immunohistochemistry for 48 CCA
tissues identified higher expression levels of histamine, HDC, and MAO-B in CCA tumors compared
to normal tissues [103]. Human CCA cell lines secreted higher levels of histamine than normal
cholangiocytes, and histamine increased tumor volumes in xenograft mouse models via elevation of
VEGF-A and VEGF-C in Mz-ChA-1 cells [103]. Administration of cromolyn sodium decreased tumor
size in Mz-ChA-1 xenograft mice, indicating that histamine promotes CCA tumor growth [104]. CCA
cells express H1 and H2 receptors, and administration of antagonists for H1 receptor (mepyramine) or
H2 receptor (ranitidine) decreased Mz-ChA-1 tumor size by decreasing expression levels of HDC and
VEGF-A in the xenograft nude mouse model in vivo [105]. These results suggest that inhibition of
histamine-H1/H2 signaling has anti-cancer effects to inhibit CCA tumor growth. However, a previous
study has demonstrated that CCA tumors and cell lines express elevated levels of H3 receptor compared
to normal tissues or cholangiocytes, and an agonist of H3 receptor (RAMH) inhibited cell proliferation
of CCA cells as well as tumor growth in xenograft mice [106]. RAMH treatments induced PKC-α
activation leading to apoptosis and decreased ERK1/2 activation leading to attenuated cell proliferation
in Mz-ChA-1 cells [106]. Another study has demonstrated that CCA tumors and cell lines also express
high levels of H4 receptor, and a H4 receptor agonist, clobenpropit, decreases CCA cell proliferation as
well as tumor volumes in Mz-ChA-1 xenograft mice by inhibiting epithelial-mesenchymal transition of
CCA cells [107]. Although histamine and its receptors are potential therapeutic targets, functional
roles of histamine receptors may differ between H1/H2 and H3/H4 receptors, and effects of histamine
may be different depending on the balance of receptor subtypes in the individual CCA tumors.
3. Conclusions and Future Perspectives
Previous studies have identified a number of neuroendocrine mediators associated with CCA
progression. Table 1 lists these mediators and compares functional roles in CCA. Many mediators were
found in PSC patients showing the association with ductular reaction and cholangiocyte proliferation,
which were also related to the regulation of CCA progression and metastases. However, some mediators
have different effects in PSC and CCA. For example, the Sct/SR axis is a well-studied signaling pathway
in animal models and its activation promotes cholangiocyte proliferation and cytokine secretion
leading to ductular reaction and liver fibrosis [108]. Although it is clear that Sct induces cholangiocyte
proliferation, a contrary effect, inhibition of CCA proliferation, has been reported [25]. The same
inconsistency was found in studies related to dopamine. Dopamine inhibited Sct-induced cAMP
elevation in cholangiocytes but promoted proliferation of CCA cell lines [89,91]. These findings suggest
that functional effects of mediators may differ when cholangiocytes become cancerous. CCA tumors
can be derived from other cell types, and mediators may affect differently in different CCA phenotypes.
In addition, there are multiple receptors for some mediators, and the effects of the mediator can
differ depending on the families or subtypes of the receptor. For example, activation of estrogen
receptor ER-α promotes CCA proliferation, but activation of ER-β inhibits CCA growth [46,47,55,56].
Although current studies have demonstrated promising therapeutic effects targeting the mediator and
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its receptor signaling pathways, further studies are required to understand differences in the efficacy
of drugs targeting these pathways depending on the origins of CCA tumors and subtypes of receptors.
Figure 1 summarizes a strategy for the development of novel CCA therapies targeting associated
signaling pathways.
Table 1. Comparison of neuroendocrine mediators associated with cholangiocarcinoma (CCA).
Mediator/Receptor Upregulated/Downregulated inCCA
Promote/Inhibit CCA
Growth Note
Hormones
Sct/SR Positive [24] Inhibit [25] Only limited numbers of CCA arepositive to SR [24]
Somatostatin/SSTR2 Positive [29] Inhibit [29,30]
May not be effective in human CCA
patients [31]
Melatonin/MT1 and MT2 Downregulated [39] Inhibit [39,40]
May also inhibit immune cell
infiltration [42]
Estrogen/ER-α and ER-β Upregulated [44] Promote [46,47]/inhibit [55,56]
Different functions between ER-α and
ER-β [46,47,55,56]
IGF-1 and IGF-2/IGF-1R
and IGF-2R Upregulated [46] Promote [46] Could be utilized as biomarkers [64,65]
Gastrin/CCK-BR Upregulated [69] Inhibit [70] Calcium-dependent [70]
Neuropeptides
NGF-β/TrkA Upregulated [73,76] Promote [74,76] May be limited in Asian patients [78]
SP/NK-1R Upregulated [82] Promote [82] Lacking evidence in humanCCA tumors
NPY/NPY receptors Upregulated [87] Inhibit [87] Limited previous studies
Neurotransmitters
Dopamine/dopamine
receptors Upregulated [91] Promote [91] Limited previous studies
Serotonin/5-HT receptors Upregulated [97] Promote [97] Functions may differ betweenreceptors [95–97]
Histamine/histamine
receptors Upregulated [103]
Promote [103–105]
inhibit [106,107]
Functions differ between H1/H2 and
H3/H4 receptors [103–107]
In conclusion, CCA tumors have altered expression levels of neuroendocrine mediators and their
receptors, and targeting these signaling pathways may be a promising approach to establish novel
treatments for CCA.
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Figure 1. Strategy for the development of novel CCA therapies. Cholangiocytes express various
receptors that interact with neuroendocrine mediators. During cholangiopathies such as primary
sclerosing cholangitis (PSC), expression levels of mediators and receptors are upregulated, which induces
cholangiocyte proliferation and secretion leading to ductular reaction and liver fibrosis. This alteration
of cholangiocyte functions may cause CCA development. Upregulation of these mediators and
receptors is also observed in CCA tumors. Inhibition of the mediator/receptor axis using antagonists
for receptors decreases cAMP levels as well as activation of PKA/ERK1/2 pathways, which attenuates
CCA progression and migration. However, effects of mediators may differ between cancerous and
non-cancerous cholangiocytes depending on the mediators. In addition, cholangiocytes may express
multiple subtypes of receptors for the specific mediators, and functions of receptors may differ between
different subtypes. Further studies are required to develop a novel drug to target the specific mediator
or receptor subtype for the regulations of CCA cell functions.
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Abbreviations
5-HT 5-hydroxytryptamine
AANAT N-acetyltransferase
ASMT acetyl serotonin O-methyltransferase
BDL bile duct ligation
CCA cholangiocarcinoma
CCK-BR cholecystokinin B receptor
CK cytokeratin
EGFR epidermal growth factor receptor
HCC hepatocellular carcinoma
HSCs hepatic stellate cells
IGF insulin-like growth factor
IL interleukin
IR insulin receptor
IP3 inositol 1,4,5-triphosphate
MAO monoamine oxidase
Mdr2 multidrug resistance protein 2
NGF nerve growth factor
NK-1R neurokinin 1 receptor
p75NTR p75 neurotrophin receptor
PKC-α protein kinase C alpha
PSC primary sclerosing cholangitis
Sct ecretin
SP substance P
SR secretin receptor
SSTR2 somatostatin receptor subtype 2
TAA thioacetamide
TAC1 tachykinin precursor 1
TrkA tropomyosin receptor kinase A
TPH tryptophan hydroxylase
VEGF vascular endothelial growth factor
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